Newswire (Published: Wednesday, August 14, 2019, Received: Wednesday, August 14, 2019, 4:37:42 PM CDT)

Word Count: 616

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Bethesda, United States, by NewsRx editors, research stated, “Current imaging and biopsy practices offer limited insight into pre-operative detection of seminal vesicle invasion despite the implications for treatment decisions and patient prognoses. We identified magnetic resonance imaging features to assess the risk of seminal vesicle invasion and inform the inclusion of seminal vesicle sampling during biopsy.”

Funders for this research include NIH (National Institutes of Health) Medical Research Scholars Program, NIH, National Cancer Institute, Center for Cancer Research, Center for Interventional Oncology, Dr. Mildred Scheel Foundation, Bonn, Germany, NIH Intramural Research Program.

Our news journalists obtained a quote from the research from National Cancer Institute, “Patients underwent multi-parametric magnetic resonance imaging and fusion targeted biopsy with or without seminal vesicle biopsy. Magnetic resonance imaging suspicion of seminal vesicle invasion, multi-parametric magnetic resonance imaging of prostate base lesions of moderate or greater suspicion, extraprostatic extension, anatomical zone and biopsy data were used to generate multivariable logistic regression models. One model without and one with biopsy data were externally validated in a multi-institutional cohort. Decision curve analyses were done to determine net benefit of the 2 models. The training and validation cohorts comprised 564 and 250 patients, respectively. In the training cohort 55 patients (9.8%) had pathologically confirmed seminal vesicle invasion. In the prebiopsy model magnetic resonance imaging suspicion of seminal vesicle invasion (OR 9.5, 95% CI 4.0-22.4, p< 0.001), multiparametric magnetic resonance imaging base lesions of moderate or greater suspicion with extraprostatic extension (OR 13.6, 95% CI 4.0-46.5, p< 0.001), and a transition and/or central zone location (OR 11.6, 95% CI 3.5-38.3, p< 0.001) showed strong correlations. In the post-biopsy model the risk of pathologically confirmed seminal vesicle invasion increased with the base Gleason Group (Gleason Group 5 OR 85.3, 95% CI 11.8-619.1, p< 0.001). In the validation cohort the AUC of the prebiopsy and post-biopsy models was 0.84 and 0.93, respectively (p = 0.030). Magnetic resonance imaging evidence of seminal vesicle invasion or extraprostatic extension at the prostate base transition and/or central zone and high grade prostate cancer from the prostate base are significant features associated with an increased risk of pathologically confirmed seminal vesicle invasion.”

According to the news editors, the research concluded: “Our models successfully incorporated these features to predict seminal vesicle invasion and inform when to biopsy the seminal vesicles.”

For more information on this research see: When To Biopsy the Seminal Vesicles: a Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model To Detect Seminal Vesicle Invasion of Prostate Cancer. The Journal of Urology, 2019;201(5):943-949. The Journal of Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

Our news journalists report that additional information may be obtained by contacting P.A. Pinto, National Cancer Institute, Urol Oncol Branch, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include S.A. Gold, J.B. Bloom, J.H. Shih, B. Turkbey, S. Rais-Bahrami, M.A. Coker, S. Vourganti, J. Fialkoff, N. Singla, C.G. Roehrborn, R.H. Baroni and J. Noschang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/JU.0000000000000112. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

National Institutes of Health
National Cancer Institute
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

North America
Western Europe
Germany
United States
Americas
Europe
Maryland
Pennsylvania
Bethesda
Philadelphia

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
            Urology